This article and associated images are based on a poster originally authored by Sophie O’Neil, Kyle Thompson, Rita Pereira, Emily Russell and Stuart McElroy and presented at ELRIG Drug Discovery 2025 ...

Scientists at UC Davis created a new class of serotonin-targeting molecules using a light-driven chemical method. UC Davis scientists have created a light-based technique that converts amino acids — t ...

Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

Research has already shown the psychedelic drug psilocybin eases depression, PTSD, and anxiety. Now researchers are working ...

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA to ...

Receptors mediate the transmission of information between nerve cells. The release of serotonin alters nerve cell activities throughout the brain. At least 14 types of serotonergic receptors can be ...